Denali Therapeutics Inc.
DNLI
$19.00
$1.166.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.39% | -25.34% | -30.62% | 3.95% | -7.89% |
| Total Depreciation and Amortization | 70.21% | 103.71% | 48.57% | -342.58% | 2.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 42.32% | 53.88% | 1,005.08% | 101.44% | 8.84% |
| Change in Net Operating Assets | -120.50% | 385.41% | -38.73% | 80.46% | 788.70% |
| Cash from Operations | -81.43% | 17.45% | -15.71% | 15.15% | 32.31% |
| Capital Expenditure | 135.48% | 10.61% | -136.19% | -127.83% | -87.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -42.12% | 56.95% | 105.28% | 135.51% | -5.28% |
| Cash from Investing | -38.25% | 60.23% | 104.14% | 135.75% | -7.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 94.33% | -- | -- | -- | -- |
| Issuance of Common Stock | -89.31% | -39.95% | -99.88% | -11.69% | 118.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 95.81% | -75.98% | -100.75% | -188.59% | -844.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -414.87% | 497.38% | -75.08% | 503.37% | -0.51% |